Enfortumab vedotin (EV) is an investigational antibody-drug conjugate (ADC) that targets Nectin-4 and is being evaluated in locally advanced or metastatic urothelial cancer who have been previously treated with both platinum chemotherapy and a checkpoint inhibitor (PD-L1 or PD-1).

Therapeutic indications
Type of product
  • Phase
    Phase II completed
  • Partnering status
  • Partner
    Astellas Pharma Inc.

You may also be interested in